



## **OXiGENE SCHEDULES SECOND QUARTER 2007 EARNINGS CONFERENCE CALL**

*--Live Internet Webcast to be Available at [www.oxigene.com](http://www.oxigene.com)--*

**WALTHAM, Massachusetts—July 18, 2007**—OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, will announce its second quarter 2007 results on Wednesday, July 25, 2007 prior to the opening of the NASDAQ Stock Market, followed by a conference call at 10:00 a.m. ET. OXiGENE's President and Chief Executive Officer, Dr. Richard Chin, Chief Scientific Officer, Dr. David Chaplin, Chief Business Officer, John Kollins and Chief Financial Officer, James Murphy, will host the call.

To listen to a live or an archived version of the audio webcast, please log on to the Company's website, [www.oxigene.com](http://www.oxigene.com). Under the "Investor Center" tab, click on the link to "Presentations & Conference Calls."

OXiGENE's earnings conference call can also be heard live by dialing (866) 290-0916 in the United States and Canada, and (913) 312-1226 for international callers, five minutes prior to the beginning of the call. A replay will be available starting at 1:00 p.m. ET on July 25, 2007 and ending at midnight ET on Tuesday, July 31, 2007. To access the replay, please dial (888) 203-1112 if calling from the United States or Canada, or (719) 457-0820 from international locations. Please refer to replay pass code 3052604.

### **About OXiGENE, Inc.**

OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

### **CONTACT:**

OXiGENE, Inc.  
Investor Relations  
781-547-5900

Or

Shari Annes, 650-888-0902